pharmaphorum June 14, 2024
Phil Taylor

The high value attached by pharma companies to inflammation and immunology (I&I) programmes is on display once again, as AbbVie agrees a deal worth up to $1.7 billion for an inflammatory bowel disease (IBD) therapy still in preclinical development.

AbbVie is paying $150 million upfront for rights to Chinese biotech FutureGen Biopharmaceutical’s FG-M701, described as a next-generation antibody that binds to tumour necrosis factor-like ligand 1A (TL1A), which has emerged as a popular new target in IBD with several candidates in a race to market.

According to AbbVie, FG-M701 could offer best-in-class functional characteristics compared to what it calls first-generation TL1A antibodies, with the potential to offer “greater efficacy and less frequent dosing as a therapy for IBD,” which includes...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Aiming to Top Amgen in Gout, Startup GRObio Gets $60M to Enter the Clinic
Ozempic Shortages Raise Questions About Prioritizing Access For Diabetics
Weight Loss Pills Intensify Obesity Drug Race—But Here’s Why Experts Say Injections Aren’t Going Anywhere
Podcast: New Alzheimer's Drug Approval Expands Treatment Options – and Creates Coverage Questions
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs

Share This Article